BOBULSKY SUSAN sold $31K of ADPT
BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 1,299 shares of Adaptive Biotechnologies Corp (ADPT) at $24.00 on 2026-07-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale details (shares, price, total value) and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may log the transaction for sentiment monitoring, but it is unlikely to drive a fresh repricing without additional company-specific catalysts.
What to watch
The sale size is small relative to typical institutional float, and the article provides no accompanying changes in guidance, trials, or financing that would make the transaction decision-relevant.
Background
The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).
Ticker impact
Adaptive Biotechnologies disclosed a Chief Commercial Officer’s open-market sale of 1,299 shares at $24.00 on 2026-07-30 via Form 4.
Likely minimal impact on the stock price; any effect is typically short-lived and outweighed by broader company catalysts.
The filing is an insider transaction (S code) explicitly tied to a pre-arranged Rule 10b5-1 plan, which generally reduces interpretive value versus discretionary selling.
Market effects
No sector-level read-through; this is company-specific insider liquidity activity.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can coincide with periods of reduced confidence, so traders may still watch for follow-on selling or other negative disclosures.
Key entities
- issuerAdaptive Biotechnologies Corp
Subject of the Form 4 insider transaction disclosure.
- insiderBOBULSKY SUSAN
Chief Commercial Officer, MRD, who sold shares.
